Navigation Links
Echosens: Launch of the FibroScan®502 Touch
Date:10/27/2011

PARIS, October 27, 2011 /PRNewswire/ --

Since its initial inception, Echosens has a history of innovation and it continues to widen and strengthen its product range with the recent introduction of the FibroScan® 502 Touch.

Equipped with a new and more ergonomic tactile interface, and based on patented Vibration-Controlled Transient Elastography (VCTE™), the latest FibroScan® provides a reliable, accurate and reproducible assessment of liver tissue stiffness.

This patented VCTE technology, developed by Echosens, is unique in measuring liver stiffness at a pre-determined and controlled 50 Hz frequency.

The FibroScan® 502 Touch offers enhanced patient data management with more complete and personalized exam reports. Compatible with the complete range of FibroScan probes (S+, M+ and XL+) it offers simultaneous connection of 2 probes giving flexibility for the patient assessment.  An indicator recommends the probe best suited to the patient's morphology.

Echosens' FS 502 Touch represents a quicker and more complete device built around the latest generation of electronics.

Continuing Echosens' history of innovation, the FS 502 Touch is further enhanced by the optional integration of the latest technological innovation: CAP™ (Controlled Attenuation Parameter), the new parameter for steatosis assessment and quantification.

Echosens has also launched new software for managing FibroScan® examinations: the Desk Solution. This comprehensive and innovative solution provides ready access to FibroScan assessments on the physician's desk-top PC.

Echosens products are widely available in most global markets and the company is actively pursuing the necessary FDA approvals to homologate its devices for sale in the United States.

About Echosens and Fibroscan®

FibroScan® is designed to quantify hepatic elasticity and steatosis in a non-invasive manner in chronic liver diseases assessment.

Founded in 2001, Echosens supplies its products in more than 70 countries through a global network of suppliers. It dedicates a major portion of its activity to research and development in order to invent new medical devices and open up new medical perspectives.  The organization works in close cooperation with health professionals and patients' associations to facilitate management and therapeutic monitoring of patients.  To date, there around 400 publications which attest to the efficacy of FibroScan in clinical practice.

Press Contact

ECHOSENS
Richard GUILLAUME
contact@echosens.com
+33-144-827850

 


'/>"/>
SOURCE Echosens
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. nContact, Inc. Launches New Corporate Websites
2. First Response Launches IVF Fundraising Resource for Those Trying for a Baby
3. Latest Pharmaceutical Launch Strategies Demonstrate Growing Importance of Thought Leader Engagement at Market Entry
4. CDC Launches Effort to Protect Cancer Patients From Infections
5. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
6. Gamma Pharmaceuticals, Inc., Launches Retail Promotions for Gamma Energy Gel™ in New York City and Houston
7. Recent Research Provides Formula for Timely Product Launch: Good Science + Effective FDA Relations
8. Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology
9. Arthrosurface Launches Worlds First Talus Resurfacing Implant for the Ankle
10. Medical Alarm and Harrington Multi Media Schedule Production for MediPendant™ National Television Launch
11. DYMO® Labeling Launches High-Resolution Identification Scanner for Health Records Processing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
(Date:5/25/2016)... May 25, 2016 According to ... Development, Growth and Demand Forecast to 2022 - Industry ... and Others)" published by P&S Market Research, the global ... in 2015, and it is expected to grow at ... the insulin pump segment is expected to witness the ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. ... been honored with a 2016 When Work Works Award for its use of effective ... the national When Work Works project administered by the Families and Work Institute (FWI) ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare ... suppliers for its inaugural Member Conference at the Paris Hotel in Las Vegas, ... operational health of America’s healthcare providers. , The conference was highlighted by the ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
(Date:5/26/2016)... ... ... The Woodlands at John Knox Village , Florida’s first Life Plan ... and healing, celebrated its grand opening, today. The Woodlands at John Knox Village is ... Staff. , “This is an incredibly fulfilling time for John Knox Village as we ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million people living ... survivors worldwide. On Sunday, June 5, 2016, communities around the world will gather to ... , National Cancer Survivors Day® is an annual worldwide Celebration of Life that ...
Breaking Medicine News(10 mins):